Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 69-71

  Lj Lazarevic, Vladimir ^a   Hägglund, Hans ^b   Remberger, Mats ^c   Wahlin, Anders ^d   Hallböök, Helene ^e   Juliusson, Gunnar ^a   Kimby, Eva ^b   Malm, Claes ^f   Omar, Hamdy ^b   Johansson, Jan Erik ^g  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOTEPA; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; ISOGRAFT; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; SWEDEN; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVORS; SWEDEN; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 78651314964     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.520777     Document Type: Article

References (16)

1. Oliansky DM, Gordon LI, King J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010;16:443-468.
2. Robinson SP, Canals C, Blaise D, et al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma results in an improved progression free survival when compared to autologous stem cell transplantation. An analysis from the Lymphoma Working Party of the EBMT. Blood 2008;112(Suppl. 1): Abstract 458.
3. Sureda A, Avivi I, Canals C, et al. Impact of the intensity of conditioning regimen in 144 patients with follicular lymphoma (FL) receiving a matched unrelated donor stem cell transplant (MUD-SCT): an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (LWP-EBMT). J Clin Oncol 2008;26(Suppl.): Abstract 7036.
4. Corradini P, Dodero A, Farina L, et al. Long-term follow-up of patients affected by relapsed lymphomas receiving reduced-intensity conditioning (RIC) regimen followed by allogeneic stem cell transplantation (allo-SCT): an update of the phase II study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Blood 2008;112(Suppl. 1): Abstract 3303.
5. Avivi I, Montoto S, Canals C, et al. EBMT Lymphoma Working Party. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2009;147:719-728.
6. van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program 2009:610-618.
7. Vigouroux S, Michallet M, Porcher R, et al. French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Long-term outcomes after reduced-intensity allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haema-tologica 2007;92:627-634.
8. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
9. Gooley T, Leisenring W, Crowley J, Storer B. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
10. Fine J, Gray R. Proportional hazard model for the sub-distribution of competing risks. J Am Stat Assoc 1999;94:496-509.
11. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lympho-ma. J Clin Oncol 2008;26:211-217.
12. Piñana JL, Martino R, Gayoso J, et al.; GELTAMO Group. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multi-center trials. Haematologica 2010;95:1176-1182.
13. Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008;111:5530-5536.
14. Erratum in: Blood 2009;113:1613.
15. Kuruvilla J, Pond G, Tsang R, Gupta V, Lipton JH, Messner HA. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. Biol Blood Marrow Transplant 2008;14:775-782.
16. Ratanatharathorn V, Logan B, Wang D, et al. Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lym-phoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009;145:816-824.